Education
About Us
Working with TipRanks
Follow Us
Medexus Pharmaceuticals Inc (TSE:MDP)
TSX:MDP
Total Valuation
Medexus Pharmaceuticals Inc has a market cap or net worth of C$92.40M. The enterprise value is C$79.31M.
Market CapC$92.40M
Enterprise ValueC$79.31M
Share Statistics
Medexus Pharmaceuticals Inc has 32,420,060 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding32,420,060
Owned by Insiders8.13%
Owned by Institutions0.03%
Financial Efficiency
Medexus Pharmaceuticals Inc’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -20.71%.
Return on Equity (ROE)>-0.01
Return on Assets (ROA)>-0.01
Return on Invested Capital (ROIC)-20.71%
Return on Capital Employed (ROCE)0.12
Revenue Per Employee1.32M
Profits Per Employee27.40K
Employee Count82
Asset Turnover0.73
Inventory Turnover1.74
Valuation Ratios
The current PE Ratio of Medexus Pharmaceuticals Inc is 133.8. Medexus Pharmaceuticals Inc’s PEG ratio is 1.50.
PE Ratio133.8
PS Ratio0.32
PB Ratio1.19
Price to Fair Value1.19
Price to FCF1.95
Price to Operating Cash Flow4.14
PEG Ratio1.50
Income Statement
In the last 12 months, Medexus Pharmaceuticals Inc had revenue of 108.33M and earned 2.25M in profits. Earnings per share was 0.09.
Revenue108.33M
Gross Profit56.58M
Operating Income8.22M
Pretax Income1.44M
Net Income2.25M
EBITDA16.81M
Earnings Per Share (EPS)0.09
Cash Flow
In the last 12 months, operating cash flow was 16.24M and capital expenditures -289.00K, giving a free cash flow of 15.95M billion.
Operating Cash Flow16.24M
Free Cash Flow15.95M
Free Cash Flow per Share0.49
Dividends & Yields
Medexus Pharmaceuticals Inc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.00
52-Week Price Change-24.80%
50-Day Moving Average2.79
200-Day Moving Average2.84
Relative Strength Index (RSI)53.49
Average Volume (3m)46.68K
Important Dates
Medexus Pharmaceuticals Inc upcoming earnings date is Feb 11, 2026, Before Open (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateFeb 11, 2026
Ex-Dividend Date―
Financial Position
Medexus Pharmaceuticals Inc as a current ratio of 1.09, with Debt / Equity ratio of 40.19%
Current Ratio1.09
Quick Ratio0.63
Debt to Market Cap1.38
Net Debt to EBITDA2.32
Interest Coverage Ratio0.81
Taxes
In the past 12 months, Medexus Pharmaceuticals Inc has paid -807.00K in taxes.
Income Tax-807.00K
Effective Tax Rate3.02
Enterprise Valuation
Medexus Pharmaceuticals Inc EV to EBITDA ratio is 4.18, with an EV/FCF ratio of 4.37.
EV to Sales0.71
EV to EBITDA4.18
EV to Free Cash Flow4.37
EV to Operating Cash Flow4.31
Balance Sheet
Medexus Pharmaceuticals Inc has C$9.38M in cash and marketable securities with C$21.07M in debt, giving a net cash position of -C$11.69M billion.
Cash & Marketable SecuritiesC$9.38M
Total DebtC$21.07M
Net Cash-C$11.69M
Net Cash Per Share-C$0.36
Tangible Book Value Per Share-C$1.98
Margins
Gross margin is 53.01%, with operating margin of 9.55%, and net profit margin of -0.19%.
Gross Margin53.01%
Operating Margin9.55%
Pretax Margin0.09%
Net Profit Margin-0.19%
EBITDA Margin17.05%
EBIT Margin11.91%
Analyst Forecast
The average price target for Medexus Pharmaceuticals Inc is C$6.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetC$6.00
Price Target Upside107.61% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast2.14%
EPS Growth Forecast-83.06%